Alta Bioscience Ltd is pleased to announce the UKAS accreditation of its urinary steroid profiling test to ISO 17025:2005.
The test is based on the GC/MS analysis of a series of up to 32 steroids and metabolites in urine to construct a ‘hormone fingerprint’. The analysis of this group of steroids has been shown by scientists at the University of Birmingham to differentiate between patients with malignant adrenal carcinoma and benign tumours. AltaBioscience has an exclusive licence on this patented technology from the University of Birmingham for this test which was developed by Professor Wiebke Arlt and Professor Paul Stewart at the University’s Institute of Metabolism and Systems Research.
Adrenal tumours are hard to detect and are often picked up from routine CT scans for other conditions. It is estimated that up to 10% of 70-80 year olds have an adrenal tumour without realising. This non-invasive test will provide clinicians and researches with a full urinary steroid profile enabling a cost effective service to aid diagnosis and progress research.
Mrs Marion Peak, Director of Operations at Alta Bioscience said, “We have been offering this test for research applications for a number of years and have a wealth of experience in this analytical procedure. UKAS accreditation to the ISO17025:2005 standard illustrates our desire to continue to offer services to the highest level of certification and will allow us to offer the test more widely”.
To request a quotation or for further information, please contact us by email (email@example.com) or telephone (+44 (0) 121 414 5450) to discuss your requirements with one of our experts.